Therapeutic drug monitoring of imatinib--new data strengthen the case.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22904104.
- Also identified by DOI 10.1158/1078-0432.CCR-12-2570.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A population pharmacokinetic study of imatinib in patients with gastrointestinal stromal tumor by Eechoute and colleagues has shown a significant increase in drug clearance over the first 3 months of treatment, resulting in a 30% decrease in drug exposure. This finding clearly shows the possibility of pharmacokinetic resistance in this disease.
Medical subject headings
- Antineoplastic Agents
- Benzamides
- Gastrointestinal Stromal Tumors
- Liver Neoplasms
- Piperazines
- Pyrimidines